Results 71 to 80 of about 10,615 (182)
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Orexin receptor-1 mediates brown fat developmental differentiation [PDF]
Orexin A (OX) is a small excitatory neuropeptide hormone that stimulates feeding, wakefulness and energy expenditure via a pair of G-coupled protein receptors, namely orexin receptor-1 (OXR1) and orexin receptor-2 (OXR2). OX-deficient mice are sensitive to obesity despite being hypophagic.
Sellayah, Dyan, Sikder, Devanjan
openaire +2 more sources
Hepatitis B virus is one of the main causes of hepatitis and hepatocellular carcinoma (HCC). Hepatitis B virus-encoded X protein (HBx) has been shown to be involved in many aspects of the pathogenicity of liver diseases.
Li Wang +4 more
doaj +1 more source
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng +3 more
wiley +1 more source
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein +10 more
wiley +1 more source
Daridorexant‐ Case Report of Possible Side‐Effect in Rare Mitochondrial Disorder
ABSTRACT This case report describes a 40‐year‐old woman with maternally inherited diabetes and deafness (MIDD), a rare mitochondrial disorder, who received treatment with daridorexant due to severe chronic insomnia. She developed progression of her MIDD symptoms during treatment.
Sven Svedmyr, Joel Bergqvist
wiley +1 more source
The metabolism of the orexin-1 selective receptor antagonist nivasorexant
Nivasorexant was the first orexin-1 selective receptor antagonist entering clinical development. Despite encouraging preclinical evidence in animal models, a proof-of-concept trial in binge-eating patients recently failed to demonstrate its clinical utility in this population.Across species, nivasorexant clearance was driven by metabolism along seven ...
Alexander, Treiber +5 more
openaire +2 more sources
Using real‐world data, AAP augmentation patterns were evaluated in patients with MDD initially treated with antidepressant monotherapy. AAP augmentation therapy was initiated after a relatively long interval. Although only a small proportion of patients received this therapy, nearly half showed claims‐defined continuation for more than 6 months ...
Hikaru Hori +8 more
wiley +1 more source
Insomnia affects around one in ten adults. In this 2‐year UK Medical Cannabis Registry cohort study of 211 adults with insomnia, treatment with cannabis‐based medicinal products was associated with a sustained improvement in self‐reported sleep quality across 24 months.
Aran Koye +7 more
wiley +1 more source
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34‐year‐old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning ...
Francois Ricordeau +8 more
wiley +1 more source

